1. Home
  2. EVGO vs TRDA Comparison

EVGO vs TRDA Comparison

Compare EVGO & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVgo Inc.

EVGO

EVgo Inc.

HOLD

Current Price

$2.79

Market Cap

396.1M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.02

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVGO
TRDA
Founded
2010
2016
Country
US
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.1M
404.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EVGO
TRDA
Price
$2.79
$11.02
Analyst Decision
Buy
Strong Buy
Analyst Count
7
2
Target Price
$5.82
$20.00
AVG Volume (30 Days)
3.5M
207.2K
Earning Date
01-01-0001
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
940.00
EPS
N/A
N/A
Revenue
N/A
$210,782,000.00
Revenue This Year
$45.28
N/A
Revenue Next Year
$29.78
$21.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
63.38
52 Week Low
$2.20
$4.93
52 Week High
$5.18
$13.82

Technical Indicators

Market Signals
Indicator
EVGO
TRDA
Relative Strength Index (RSI) 40.49 52.75
Support Level $2.67 $10.48
Resistance Level $3.32 $11.43
Average True Range (ATR) 0.18 0.74
MACD -0.03 -0.03
Stochastic Oscillator 16.15 56.11

Price Performance

Historical Comparison
EVGO
TRDA

About EVGO EVgo Inc.

EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: